Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $150K | $120K | $89.8K | $158K | $33.0K | $3.19M | $1.10M | — | — |
| Revenue growth | — | — | -20.0% | -25.0% | 76.3% | -79.2% | 9560.6% | -65.6% | — | — |
| Operating income | -$8.26M | -$16.5M | -$14.6M | -$18.9M | -$24.2M | -$24.7M | -$24.6M | -$23.8M | -$24.6M | -$6.96M |
| Operating margin | — | -11024.6% | -12230.9% | -21067.4% | -15288.4% | -74954.5% | -771.3% | -2168.4% | — | — |
| Net income | -$7.60M | -$15.5M | -$14.1M | -$17.4M | -$22.4M | -$23.3M | -$21.0M | -$22.9M | -$24.3M | -$10.3M |
| Net margin | — | -10345.9% | -11760.4% | -19343.4% | -14177.0% | -70554.5% | -658.6% | -2093.2% | — | — |
| EPS (diluted) | -$0.21 | -$0.36 | -$0.15 | -$0.13 | -$0.12 | -$0.11 | -$0.10 | -$5.28 | -$4.98 | -$2.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.12M | -$11.5M | -$10.3M | -$14.1M | -$17.4M | -$15.2M | -$19.2M | -$15.3M | -$15.9M | -$7.01M |
| Capital expenditures | $0.00 | $942K | $536K | $406K | $5.75K | $260K | $892K | $218K | — | — |
| Free cash flow | -$6.12M | -$12.4M | -$10.9M | -$14.5M | -$17.4M | -$15.5M | -$20.0M | -$15.5M | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.11M | $7.31M | $12.4M | $22.2M | $12.4M | $21.0M | $6.83M | $4.79M | $7.28M | $4.00M |
| Total assets | $9.82M | $14.4M | $19.9M | $40.2M | $71.0M | $61.3M | $44.8M | $25.1M | $12.6M | $7.21M |
| Total liabilities | $2.67M | $3.74M | $3.80M | $7.19M | $7.24M | $8.83M | $8.18M | $5.86M | $5.05M | $2.38M |
| Shareholders' equity | $7.15M | $10.7M | $16.1M | $33.1M | $63.7M | $52.5M | $36.6M | $19.2M | $7.59M | $4.83M |
| Retained earnings | -$35.2M | -$51.3M | -$65.9M | -$84.4M | -$108M | -$132M | -$153M | -$176M | -$200M | -$211M |
| Shares (wtd avg diluted) | 58.2M | 93.4M | 113M | 163M | 200M | 210M | 217M | 4.35M | 4.87M | 5.47M |
Every figure is extracted from Matinas BioPharma Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.